XYOSTED

Bucking the trend, Antares gains FDA OK for testosterone rejection on second try
Endpoints
Tue, 10/2/18 - 10:05 am
Antares Pharma
XYOSTED
testosterone
FDA
Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates
Yahoo/Benzinga
Sat, 09/1/18 - 03:38 pm
biotech
FDA
Roche
Tecentriq
GSK
mepolizumab
Teva Pharmaceutical
fremanezumab
Adamis Pharmaceuticals
Symjepi
Insmed
ALIS
Antares
XYOSTED
Eli Lilly
galcanezumab
Pfizer
dacomitinib